The NCL has just added a new protocol to our Assay Cascade Protocols page to measure drug release from nanomedicines.
Nanotechnology Characterization Lab
Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.
There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.
News & Updates
More than 200 science and business professionals from across the region attended the Frederick National Laboratory for Cancer Research’s (FNLCR) Inaugural Technology Showcase...
NCI’s Office of Cancer Nanotechnology Research has published a new funding opportunity announcement (FOA) for the Innovative Research in Cancer Nanotechnology (IRCN) initiative...
- 1 of 2
- next ›
Meet Us @
The Office of Generic Drugs is hosting a one day public workshop to highlight GDUFA funded research on demonstrating the equivalence of complex drug substances and formulations...
The World Drug Delivery Summit will be in Baltimore, Maryland, October 16-18th.
The 2017 PDA Endotoxins Workshop will take place in Bethesda, MD. The two-day event will cover topics such as
- 1 of 2
- next ›